Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Anti-GD2 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Sponsors Sinobioway Cell Therapy
Most Recent Events
- 06 Oct 2016 New trial record